FUNDAMENTALS |
MarketCap: |
4.09 mill
|
EPS: |
-0.360
|
P/E: |
-0.0811
|
Earnings Date: |
Aug 09, 2023 |
SharesOutstanding: |
140.03 mill
|
Avg Daily Volume: |
10.09 mill
|
RATING
2023-05-23 |
S-
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Neutral
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Strong Buy
|
|
DE: |
Strong Buy
|
|
P/E: |
Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 |
Revenue | n/a | n/a | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | n/a | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.0811 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
0x
|
Company: PE -0.0811 | industry: PE -4.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ -0.0262 - 0.0358
( +/- 645.83%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2023-04-10 | 5am Partners Iv, Llc | Sell | 3 172 769 | Class A Common Stock |
2023-04-10 | 5am Partners Iv, Llc | Sell | 534 855 | Class A Common Stock |
2023-02-15 | Snow Ellen | Buy | 199 864 | Restricted Stock Units |
2023-02-16 | Snow Ellen | Buy | 40 000 | Restricted Stock Units |
2023-02-15 | Brenner Erin K. | Buy | 952 380 | Restricted Stock Units |
INSIDER POWER |
29.86
|
Last
97 transactions |
Buy:
13 156 765 | Sell:
6 479 057 |
Forecast:
01:40 - $-0.200
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$0.0292 (0.00% )
|
Volume |
66.30 mill
|
Avg. Vol. |
10.09 mill
|
% of Avg. Vol |
657.35 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For PEAR
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.